Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 52.63, which is an increase of 38% from the previous target price of RMB 38.24 [1][4]. Core Insights - The report highlights that the geopolitical conflicts in the Middle East have led to increased prices and supply shortages of key raw materials such as LNG, methanol, propane/propylene, and sulfur, which are essential for the production of methionine. This instability in raw material supply is expected to drive up methionine prices, benefiting the company due to its relatively stable domestic raw material and energy supply [1][2]. - The company is projected to gain market share globally as its production capacity for methionine and vitamins is more competitive compared to overseas firms, especially in the context of declining overseas supply stability [1][3]. - The report anticipates a continued upward trend in methionine prices, with a forecasted net profit of RMB 67 billion, RMB 85 billion, and RMB 96 billion for the years 2025 to 2027, respectively, reflecting a compound annual growth rate (CAGR) of 18% [4]. Summary by Sections Supply and Demand Dynamics - Since the end of February, geopolitical tensions have caused price increases and supply shortages for raw materials like natural gas and sulfur, impacting overseas methionine production. Companies such as Winco and Sumitomo Chemical have declared force majeure due to these supply issues [2]. - The domestic methionine market price as of March 10 was RMB 28.75 per kg, a 63% increase since the beginning of the year, indicating a significant widening of the price gap compared to international markets [2]. Vitamin Market Outlook - The vitamin market, particularly for Vitamin E, has also shown signs of improvement, with prices rising to RMB 68.5 per kg, a 23% increase since the start of the year. The report suggests that supply constraints from overseas will further enhance the company's market position [3]. Financial Projections - The company’s projected revenues for 2024, 2025, 2026, and 2027 are RMB 21.61 billion, RMB 23.88 billion, RMB 27.88 billion, and RMB 31.05 billion, respectively, with corresponding net profits of RMB 5.87 billion, RMB 6.73 billion, RMB 8.51 billion, and RMB 9.63 billion [10][33]. - The report estimates an increase in the company's net profit forecasts for 2026 and 2027 by 16% and 19%, respectively, due to the anticipated rise in methionine prices [4].

证券研究报告 新和成 (002001 CH) 海外供给收缩有望助力产品景气上行 | 华泰研究 | | | 动态点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | --- | | 2026 年 | 3 月 | 10 日│中国内地 | 化学制品 | 目标价(人民币): | 52.63 | 2 月底以来，伊朗及中东地区地缘冲突下，中东部分国家能源设施受损及霍 尔木兹海峡运输受阻等因素，导致全球 LNG、甲醇、丙烷/丙烯、硫磺等提 价及缺货担忧。由于天然气/甲醇/丙烯/硫磺是蛋氨酸生产的主要原材料，原 料供应不稳定及提价导致的海外供给隐忧，有望带动蛋氨酸价格持续上行， 新和成基于国内原料和能源供应相对稳定性或充分受益。中长期而言，新和 成蛋氨酸、维生素等产能，由于能源、劳动力和制造成本等综合竞争力相较 海外企业显著占优，在海外供应稳定性下降及潜在退出环境下，公司全球份 额有望持续增长。考虑到蛋氨酸等景气上行，我们上调公司 27-28 年归母净 利润预测，上调目标价至 52.63 元（上调 38%），维持"买入"评级。 能源/原料供应压力冲击海外产能，蛋氨酸供需向 ...